These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15096073)

  • 21. Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care.
    Stant AD; TenVergert EM; Kluiter H; Conradi HJ; Smit A; Ormel J
    J Ment Health Policy Econ; 2009 Dec; 12(4):195-204. PubMed ID: 20195007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic implications of treatment-resistant depression among employees.
    Greenberg P; Corey-Lisle PK; Birnbaum H; Marynchenko M; Claxton A
    Pharmacoeconomics; 2004; 22(6):363-73. PubMed ID: 15099122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incremental Benefit-Cost of MOMCare: Collaborative Care for Perinatal Depression Among Economically Disadvantaged Women.
    Grote NK; Simon GE; Russo J; Lohr MJ; Carson K; Katon W
    Psychiatr Serv; 2017 Nov; 68(11):1164-1171. PubMed ID: 28669288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human cost of not achieving full remission in depression.
    McIntyre RS; O'Donovan C
    Can J Psychiatry; 2004 Mar; 49(3 Suppl 1):10S-16S. PubMed ID: 15147032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.
    Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J
    J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in health care use and costs after a break in Medicaid coverage among persons with depression.
    Harman JS; Hall AG; Zhang J
    Psychiatr Serv; 2007 Jan; 58(1):49-54. PubMed ID: 17215412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial.
    Horn EK; van Benthem TB; Hakkaart-van Roijen L; van Marwijk HW; Beekman AT; Rutten FF; van der Feltz-Cornelis CM
    BMC Health Serv Res; 2007 Feb; 7():28. PubMed ID: 17324283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A closer look at treatment resistant depression: is it due to a bipolar diathesis?
    Sharma V; Khan M; Smith A
    J Affect Disord; 2005 Feb; 84(2-3):251-7. PubMed ID: 15708423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment-resistant depression: managed care considerations.
    Tierney JG
    J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S2-7. PubMed ID: 17672818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
    McCombs JS; Ahn J; Tencer T; Shi L
    J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support.
    Wade AG; Häring J
    Int Clin Psychopharmacol; 2010 Sep; 25(5):288-96. PubMed ID: 20715299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.
    Ivanova JI; Birnbaum HG; Kidolezi Y; Subramanian G; Khan SA; Stensland MD
    Curr Med Res Opin; 2010 Oct; 26(10):2475-84. PubMed ID: 20825269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
    Asche CV; Joish VN; Camacho F; Drake CL
    Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of transcranial magnetic stimulation in treatment-resistant depression: a review.
    Lee JC; Blumberger DM; Fitzgerald PB; Daskalakis ZJ; Levinson AJ
    Curr Pharm Des; 2012; 18(36):5846-52. PubMed ID: 22681165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus.
    Simon GE; Katon WJ; Lin EH; Rutter C; Manning WG; Von Korff M; Ciechanowski P; Ludman EJ; Young BA
    Arch Gen Psychiatry; 2007 Jan; 64(1):65-72. PubMed ID: 17199056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.